Anthera Pharmaceuticals 

We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Find out more about what we are doing for patients with Cystic Fibrosis and IgA Nephropathy:

Cystic Fibrosis
IgA Nephropathy

Anthera Pharmaceuticals Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results – Additional Study Needed. Read more

Anthera Pharmaceuticals Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of Blisibimod for IgA Nephropathy. Read more

Print Friendly